

Evrysdi™ (risdiplam) Solution and Tablets (Oral)

Effective Date: 01/01/2021

Reviewed Date: 10/2020, 6/2021, 04/2022, 03/2023, 03/2024, 02/2025, 04/2025

Scope: Medicaid

I. Length of Authorization

Coverage will be provided every 6 months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- 5mg per day
- Evrysdi 60 mg oral solution: 2 bottles every 24 days (6.67 mL per day)
- Evrysdi 5 mg tablet: 1 tablet daily

III. Initial Approval Criteria¹⁻⁶

Universal Criteria

- Patient must not have previously received treatment with SMA gene therapy (i.e., onasemnogene abeparvovec-xioi); **AND**
- Patient will not use in combination with other agents for SMA (e.g., onasemnogene abeparvovec, nusinersen, etc.); **AND**
- Patient must not have advanced disease (e.g., complete limb paralysis, permanent ventilation support or have a tracheostomy, etc.); **AND**
- Documentation of the patient's current weight and age are provided; **AND**
- Dose does not exceed FDA approved labeling for the patient's weight and age; **AND**

Spinal Muscular Atrophy (SMA) † Φ¹⁻⁶

- Patient retains meaningful voluntary motor function (e.g. manipulate objects using upper extremities, ambulate, etc.); **AND**
- Patient must have a diagnosis of 5q spinal muscular atrophy confirmed by either homozygous deletion of the *SMN1* gene or dysfunctional mutation of the *SMN1* gene; **AND**
- Patient must have a documented diagnosis of SMA phenotype I, II, or III; **AND**
 - Patient has ≤ 3 copies of the *SMN2* gene; **OR**

- Patient has symptomatic disease (i.e., impaired motor function and/or delayed motor milestones); AND
- Baseline documentation of one or more of the following:
 - Motor function/milestones, including but not limited to, the following validated scales: Hammersmith Infant Neurologic Exam (HINE), Hammersmith Functional Motor Scale Expanded (HFMSSE), Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), Bayley Scales of Infant and Toddler development Third Ed. (BSID-III), 6-minute walk test (6MWT), upper limb module (ULM), motor function measure 32 (MFM32), revised upper limb module (RULM), etc.
 - Respiratory function tests [e.g., forced vital capacity (FVC), etc.]
 - Exacerbations necessitating hospitalization and/or antibiotic therapy for respiratory infection in the preceding year/timeframe
 - Patient weight (for patients without a gastrostomy tube)

† FDA-labeled indication(s), ‡ Compendia recommended indication(s); Ⓢ Orphan Drug

IV. Renewal Criteria¹⁻⁶

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), etc. identified in section III; **AND**
- Patient will not use in combination with other agents for SMA (e.g., onasemnogene abeparvovec, nusinersen, etc.); **AND**
- Absence of unacceptable toxicity, which would preclude safe administration of the drug. Examples of unacceptable toxicity include the following: severe diarrhea, etc.; **AND**
- Patient has responded to therapy compared to pretreatment baseline in one or more of the following:
 - Stability or improvement in net motor function/milestones, including but not limited to, the following validated scales: Hammersmith Infant Neurologic Exam (HINE), Hammersmith Functional Motor Scale Expanded (HFMSSE), Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), Bayley Scales of Infant and Toddler development Third Ed. (BSID-III), 6-minute walk test (6MWT), upper limb module (ULM), motor function measure 32 (MFM32), revised upper limb module (RULM), etc.
 - Stability or improvement in respiratory function tests [e.g., forced vital capacity (FVC), etc.]
 - Reduction in exacerbations necessitating hospitalization and/or antibiotic therapy for respiratory infection in the preceding year/timeframe
 - Stable or increased patient weight (for patients without a gastrostomy tube)
 - Slowed rate of decline in the aforementioned measures

Commented [AM1]: CVS policy uses HINE-2 as one of the scales measuring motor function that can be used to provide documentation for initiation or renewal, while we only have HINE as a scale on our policy. From some research I found that HINE-2 is a subsection of the HINE scale that focuses solely on the motor milestones of an infant. Pretty much HINE-2 is a simplified version of HINE. I am not too sure which is more used in clinical practice, but I did find HINE-2 is commonly used in clinical trials. More specifically it was the scale used in the approval trials for Evrysdi.

V. Dosage/Administration

Indication	Dose
Spinal Muscular Atrophy	<p>Evrysdi is administered orally once daily. The recommended dosage is determined by age and body weight, as follows:</p> <ul style="list-style-type: none"> • Less than 2 months of age: 0.15mg/kg • 2 months to < 2 years of age: 0.2 mg/kg • 2 years of age and older weighing < 20 kg: 0.25 mg/kg • 2 years of age and older weighing ≥ 20 kg: 5 mg
<p>Store the constituted oral solution of Evrysdi in the original amber bottle to protect from light. Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Discard any unused portion after 64 days.</p>	

VI. Billing Code/Availability Information

NDC:

Evrysdi 0.75 mg/mL oral solution – 60 mg glass bottle: 50242-0175-xx

Evrysdi 5 mg tablet- 30 count bottle: 50242-0202-xx

VII. References

1. Evrysdi [package insert]. South San Francisco, CA; Genentech, Inc.; October 2023. Accessed April 2025.
2. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. *J Child Neurol.* 2007 Aug;22(8):1027-49.
3. Prior TW, Finanger E. Spinal muscular atrophy. *GeneReviews.* www.ncbi.nlm.nih.gov/books/NBK1352/ (Accessed on August 13, 2020).
4. Kichula E, Duong T, Glanzman A, et al. Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Feasibility for Individuals with Severe Spinal Muscular Atrophy II (S46.004). *Neurology* Apr 2018, 90 (15 Supplement) S46.004
5. Hoffman-La Roche. Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type 1 Spinal Muscular Atrophy (FIREFISH). Available from: <https://clinicaltrials.gov/ct2/show/NCT02913482?term=NCT02913482&draw=2&rank=1>. NLM identifier: NCT02913482. Accessed August 13, 2020.
6. Hoffman-La Roche. A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants (SUNFISH). Available from: <https://clinicaltrials.gov/ct2/show/NCT02908685?term=NCT02908685&draw=2&rank=1>. NLM identifier: NCT02908685. Accessed August 13, 2020.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
G12.0	Infantile spinal muscular atrophy, type I [Werdnig-Hoffmann]

ICD-10	ICD-10 Description
G12.1	Other inherited spinal muscular atrophy
G12.25	Progressive spinal muscle atrophy
G12.8	Other spinal muscular atrophies and related syndromes
G12.9	Spinal muscular atrophy, unspecified